These findings critical insight into the mechanism of EBV-mediated NPC development and implicate that SPLUNC1 could be exploited in the development of targeted therapies and serve as a diagnostic and prognostic factor for NPC. This evidence concerns the gene BPIFA1 and nasopharyngeal carcinoma.